EMA — authorised 17 December 2004
- Application: EMEA/H/C/000572
- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Local brand name: Cymbalta
- Indication: Treatment of major depressive disorder. Treatment of diabetic peripheral neuropathic pain. Treatment of generalised anxiety disorder. Cymbalta is indicated in adults.
- Status: approved